TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

LATEST NEWS

4 Stocks Under $10 Making Big Moves
INVESTING

5 Breakout Stocks Ready to Surge Higher

5 Stocks Insiders Love Right Now
INVESTING

4 Hot Stocks to Trade (or Not)

3 Stocks Breaking Out on Unusual Volume
INVESTING

5 Big Stocks to Trade (or Not)

5 Stocks Set to Soar on Bullish Earnings
INVESTING

4 Biotech Stocks Under $5 to Watch

Biotech Stock Mailbag: Biogen's Alzheimer's Update, Celgene Patent Worries, Receptos, MannKind
STOCKS

Biotech Stock Mailbag: Delcath, Navidea, Affymax, Ziopharm

3 Stocks Breaking Out on Unusual Volume
INVESTING

5 Stocks Ready to Break Out

5 Heavily Shorted Stocks Set to Soar on Bullish Earnings
INVESTING

5 Stocks Poised for Breakouts

Perilous Reversal Watch: Yamana Gold (AUY)
MARKETS

3 Stocks Pushing The Drugs Industry Lower

Sangamo's HIV Gene Therapy Is a Valuation Prop, Nothing More
STOCKS

Affymax Is Done. RIP.

CTI Biopharma Posts Positive Myelofibrosis Study Results
STOCKS

10 Best-Performing Biopharma Stocks of 2012 and Their 2013 Outlook

5 Stocks Insiders Love Right Now
INVESTING

3 Stocks Rising on Unusual Volume

5 Stocks Poised for Breakouts
MARKETS

4 Health Care Stocks Rising on Big Volume

Inflating Market Bubble Not Quite Ready to Pop
MARKETS

4 Stocks Moving Higher With Volume

Jim Cramer's 'Mad Money' Recap: Fear and Loathing on Wall Street
JIM CRAMER

Cramer's 'Mad Money' Recap: When Progress Isn't Good

Gilead Sciences Buying Achillion Was Twitter Speculation at Its Finest
STOCKS

Nektar Therapeutics Is a Short

Earnings Preview: Dow Stocks J&J, Travelers and Verizon Report Premarket Tuesday
MARKETS

4 Big-Volume Stocks Surging Higher

Could This Biotech Stock Be First to Break Feuerstein-Ratain Rule?
STOCKS

Biotech Stock Mailbag: Amarin or Arena Takeout?

Hedge Funds Love These 5 Consumer Stocks -- but Should You?
INVESTING

8 Stocks Rising on Monster Volume

MannKind Afrezza Contributes to Sanofi's Subpar Diabetes Unit Sales
STOCKS

Biotech Stock Mailbag: MAP Pharma, Affymax

5 Hated Earnings Stocks You Should Love
INVESTING

8 Stocks Rising on Huge Volume

Gilead Sciences Buying Achillion Was Twitter Speculation at Its Finest
STOCKS

Biotech Stock Mailbag: Xoma's Big Backers, FDA Approvals Contest

The Next Big Thing in Biotech: FDA Decisions
VIDEO

The Next Big Thing in Biotech: FDA Decisions

Vertex Pharma Cystic Fibrosis FDA Advisory Panel Live Blog
INVESTING

Biotech Stock Chat: Recap

4 Under-$10 Biotech Stocks in Breakout Territory
INVESTING

5 Stocks Ready to Soar on Bullish Earnings

Genfit Digs Even Deeper to Find Hidden Benefit in Fatty Liver Drug
STOCKS

More Biotech Twitter Mailbag: Orexigen, Affymax, YM Bio, Spectrum & More